Financial News

Financial Report: Gilead

HCV sales down 18% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead 2Q Revenues: $7.8 billion (-6%) 2Q Earnings: $3.5 billion (-22%) YTD Revenues: $15.6 billion (-2%) YTD Earnings: $7.1 billion (-20%) Comments: Product sales for the quarter were $7.7 billion, down 5, with $4.9 billion in the U.S., down 13%, $1.6 billion in Europe, down 20%, $619 million in Japan compared to $62 million 2Q15, and $531 million in other locations, up 3%. HIV and other antiviral product sales were $3.1 billion, up 15% primarily due to increases in sales of teno...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters